Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Index pricing vs no index pricing Healthcare utilisation · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin… Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Index pricing vs no index pricing Health outcomes · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin… Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Index pricing vs no index pricing Adverse events · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin… Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Index pricing vs no index pricing CI: Confidence interval · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin… Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Maximum prices vs no maximum prices Drug prices · Patients taking statins Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Maximum prices vs no maximum prices Healthcare utilisation · Patients taking statins Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Maximum prices vs no maximum prices Health outcomes · Patients taking statins Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Maximum prices vs no maximum prices Drug use · Patients taking statins Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Maximum prices vs no maximum prices Adverse events · Patients taking statins Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Maximum prices vs no maximum prices CI: Confidence interval · Patients taking statins Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Reference pricing policy vs no reference pricing Healthcare utilisation · Patients with drug insurance Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Reference pricing policy vs no reference pricing Health outcomes · Patients with drug insurance Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Reference pricing policy vs no reference pricing Adverse events · Patients with drug insurance Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Index pricing vs no index pricing Drug expenditures · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin… Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014) · Cochrane | no estimate extracted | NR | No studies |
Cyst aspiration vs conservative management Live birth rate · women with subfertility Ovarian cyst aspiration prior to in vitro fertilization treatment for subfertility (2014) · Cochrane | no estimate extracted | NR | No studies |
Cyst aspiration vs conservative management Adverse events rate · women with subfertility Ovarian cyst aspiration prior to in vitro fertilization treatment for subfertility (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily Pain reduction ‐ not measured · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily Function ‐ not measured · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol 100‐300 mg daily vs febuxostat 80 mg daily Tophus regression · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol vs benzbromarone Pain reduction ‐ not measured · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol vs benzbromarone Function ‐ not measured · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol vs benzbromarone Tophus regression ‐ not reported · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol vs benzbromarone Serious adverse effects · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol vs placebo Function · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Allopurinol vs placebo Tophus regression · people with chronic gout Allopurinol for chronic gout (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Complications of diabetes mellitus · ethnic minority groups with type 2 diabetes mellitus Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause and specific mortality · ethnic minority groups with type 2 diabetes mellitus Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · ethnic minority groups with type 2 diabetes mellitus Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus (2014) · Cochrane | no estimate extracted | NR | No studies |
Paroxetine vs citalopram Failure to remit at endpoint · patients with depression Paroxetine versus other anti‐depressive agents for depression (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE General functioning ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 2. ARIPIPRAZOLE vs QUETIAPINE Service use ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE Quality of life ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE General functioning ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 3. ARIPIPRAZOLE vs RISPERIDONE Service use ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE Quality of life ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE General functioning ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 4. ARIPIPRAZOLE vs ZIPRASIDONE Service use ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE General functioning ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 5. ARIPIPRAZOLE vs OLANZAPINE Service use ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE General functioning ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
COMPARISON 1. ARIPIPRAZOLE vs CLOZAPINE Service use ‐ not measured · patients with schizophrenia Aripiprazole versus other atypical antipsychotics for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR "Moderate" benefit At least 30% reduction in pain · Adults with cancer pain Codeine, alone and with paracetamol (acetaminophen), for cancer pain (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Proportion below 30/100 mm on VAS · Adults with cancer pain Codeine, alone and with paracetamol (acetaminophen), for cancer pain (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient Global Impression of Change much or very much improved · Adults with cancer pain Codeine, alone and with paracetamol (acetaminophen), for cancer pain (2014) · Cochrane | no estimate extracted | NR | No studies |
Alpha blocker vs placebo or control Need for prostatic surgery ‐ not reported · acute urinary retention in adult men The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men (2014) · Cochrane | no estimate extracted | NR | No studies |
Alpha blocker vs placebo or control Condition‐specific QoL ‐ not reported · acute urinary retention in adult men The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men (2014) · Cochrane | no estimate extracted | NR | No studies |
Alpha blocker vs placebo or control Cost effectiveness ‐ not reported · acute urinary retention in adult men The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men (2014) · Cochrane | no estimate extracted | NR | No studies |
Music vs standard care CI: Confidence interval · mechanically ventilated patients Music interventions for mechanically ventilated patients (2014) · Cochrane | no estimate extracted | NR | No studies |
Intranasal neostigmine vs placebo Change in impairment 1 to 14 days after the start of treatment ‐ not reported · people with myasthenia gravis Acetylcholinesterase inhibitor treatment for myasthenia gravis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Objective physiological measures Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps (2014) · Cochrane | no estimate extracted | NR | No studies |